Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous vedolizumab TDM-guided de-escalation in inflammatory bowel disease
2022-000837-17Phase 4Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vedolizumab in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Cost-effectiveness of TDM-guided de-escalation vs standard dosing over 48 weeks. Started Sep 2022; status: active.
02
Drugs
vedolizumab
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2022-000837-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000837-17.